Loading…
A bill to amend the Controlled Substances Act to address the use of intrathecal pumps.
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 4,048 other S bills in the 111th — cohort avg 29d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2011 · first_quarter · Pharmacy
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet. Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet. H.R. 3018 and S. 3274, To amend the Controlled Substances Act to address the use of intrathecal pumps. Amends the Controlled Substances Act to revise the definition of "dispense" to include the delivery of a controlled substance through the use of an intrathecal pump by a practitioner acting in the usual course of professional practice.
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $11,508
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Pharmacy
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet. Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet. H.R. 3018 and S. 3274, To amend the Controlled Substances Act to address the use of intrathecal pumps. Amends the Controlled Substances Act to revise the definition of "dispense" to include the delivery of a controlled substance through the use of an intrathecal pump by a practitioner acting in the usual course of professional practice.
Client expense: Not reported · Firm income: $11,250
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Pharmacy
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet. Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet. H.R. 3018 and S. 3274, To amend the Controlled Substances Act to address the use of intrathecal pumps. Amends the Controlled Substances Act to revise the definition of "dispense" to include the delivery of a controlled substance through the use of an intrathecal pump by a practitioner acting in the usual course of professional practice.
Client expense: Not reported · Firm income: $11,250
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Pharmacy
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation has been introduced yet. Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet. H.R. 3018 and S. 3274, To amend the Controlled Substances Act to address the use of intrathecal pumps. Amends the Controlled Substances Act to revise the definition of "dispense" to include the delivery of a controlled substance through the use of an intrathecal pump by a practitioner acting in the usual course of professional practice.
Client expense: Not reported · Firm income: $6,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · fourth_quarter · Pharmacy
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation has been introduced yet. Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet. H.R. 3018 and S. 3274, To amend the Controlled Substances Act to address the use of intrathecal pumps. Amends the Controlled Substances Act to revise the definition of "dispense" to include the delivery of a controlled substance through the use of an intrathecal pump by a practitioner acting in the usual course of professional practice.
Client expense: Not reported · Firm income: $11,250
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Health Issues
radiation exposure compensation S.1515 health care safety net amendments S,.1281 assocation health plans H.R. 660/S.545 asbestos compensation reform S.2290 asbestos litigation S.853 & H.R.1360 asbestos litigation S.3274 & H.R. 1360 Health Care Reform Bill
Client expense: $10,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Pharmacy
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation has been introduced yet. Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet. H.R. 3018 and S. 3274, To amend the Controlled Substances Act to address the use of intrathecal pumps. Amends the Controlled Substances Act to revise the definition of "dispense" to include the delivery of a controlled substance through the use of an intrathecal pump by a practitioner acting in the usual course of professional practice.
Client expense: Not reported · Firm income: $6,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Pharmacy
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet. Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet. H.R. 3018 and S. 3274, To amend the Controlled Substances Act to address the use of intrathecal pumps. Amends the Controlled Substances Act to revise the definition of "dispense" to include the delivery of a controlled substance through the use of an intrathecal pump by a practitioner acting in the usual course of professional practice.
Client expense: Not reported · Firm income: $11,250
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · third_quarter · Pharmacy
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet. Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet. H.R. 3018 and S. 3274, To amend the Controlled Substances Act to address the use of intrathecal pumps. Amends the Controlled Substances Act to revise the definition of "dispense" to include the delivery of a controlled substance through the use of an intrathecal pump by a practitioner acting in the usual course of professional practice.
Client expense: Not reported · Firm income: $11,250
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · second_quarter · Health Issues
radiation exposure compensation S.1515 health care safety net amendments S,.1281 assocation health plans H.R. 660/S.545 asbestos compensation reform S.2290 asbestos litigation S.853 & H.R.1360 asbestos litigation S.3274 & H.R. 1360 Health Care Reform Bill
Client expense: $10,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · second_quarter · Pharmacy
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet. Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet. H.R. 3018 and S. 3274, To amend the Controlled Substances Act to address the use of intrathecal pumps. Amends the Controlled Substances Act to revise the definition of "dispense" to include the delivery of a controlled substance through the use of an intrathecal pump by a practitioner acting in the usual course of professional practice.
Client expense: Not reported · Firm income: $11,250
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2010 · first_quarter · Health Issues
radiation exposure compensation S.1515 health care safety net amendments S,.1281 assocation health plans H.R. 660/S.545 asbestos compensation reform S.2290 asbestos litigation S.853 & H.R.1360 asbestos litigation S.3274 & H.R. 1360 Health Care Reform Bill
Client expense: $10,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · fourth_quarter · Health Issues
radiation exposure compensation S.1515 health care safety net amendments S,.1281 assocation health plans H.R. 660/S.545 asbestos compensation reform S.2290 asbestos litigation S.853 & H.R.1360 asbestos litigation S.3274 & H.R. 1360 Health Care Reform Bill
Client expense: $10,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · third_quarter · Health Issues
radiation exposure compensation S.1515 health care safety net amendments S,.1281 assocation health plans H.R. 660/S.545 asbestos compensation reform S.2290 asbestos litigation S.853 & H.R.1360 asbestos litigation S.3274 & H.R. 1360 Health Care Reform Bill
Client expense: $10,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · second_quarter · Health Issues
radiation exposure compensation S.1515 health care safety net amendments S,.1281 assocation health plans H.R. 660/S.545 asbestos compensation reform S.2290 asbestos litigation S.853 & H.R.1360 asbestos litigation S.3274 & H.R. 1360 Health Care Reform Bill
Client expense: $10,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · first_quarter · Health Issues
radiation exposure compensation S.1515 health care safety net amendments S,.1281 assocation health plans H.R. 660/S.545 asbestos compensation reform S.2290 asbestos litigation S.853 & H.R.1360 asbestos litigation S.3274 & H.R. 1360
Client expense: $10,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE